Gilead Sciences will share new Phase III trial data showing that twice-yearly lenacapavir (Yeztugo) was effective and well tolerated among a broad range of populations who need or want pre-exposure prophylaxis (PrEP) for HIV prevention. 

The new data, from the company’s pivotal Phase III PURPOSE 1 and PURPOSE 2 trials that assessed the efficacy and safety of twice-yearly Yeztugo for PrEP, will be presented at the International AIDS Society (IAS) 2025, the 13th IAS Conference on HIV Science in Kigali, Rwanda.  

The data presentations come less than a month after the US Food and Drug Administration (FDA) approved Yeztugo as the first twice-yearly HIV prevention option.  

“It’s a thrill to be back in Kigali with so many of the community, advocacy and research partners who helped make PURPOSE the most intentionally inclusive HIV prevention trial programme ever conducted,” said Moupali Das, Vice President of Clinical Development, HIV Prevention & Pediatrics at Gilead Sciences. “As the first and only twice-yearly PrEP option, Yeztugo continues to demonstrate efficacy and tolerability among diverse populations, and we’re excited to highlight new data on this breakthrough HIV prevention option here at IAS 2025.” 

Inclusive clinical trial

The PURPOSE 1 trial and the PURPOSE 2 trial evaluated twice-yearly Yeztugo among a broad and geographically diverse range of cisgender women, men and gender-diverse people. 

The data show that Yeztugo was efficacious in pregnant and breastfeeding or lactating women, with no new cases of HIV reported among 184 participants in the Yeztugo group (there were a total of 509 pregnancies among 487 participants in PURPOSE 1).  

Data also show that Yeztugo was well tolerated by these women, that there were similar safety profiles between pregnant and non-pregnant women, and that there were no clinically significant differences in predicted Yeztugo exposure by pregnancy trimester or postpartum status. Additionally, exposure in breastfed infants was minimal. 

In addition, Yeztugo was efficacious in people aged 16-25 years, with zero reported HIV infections in young people receiving Yeztugo in PURPOSE 1 and two HIV infections among young people in PURPOSE 2. Additionally, there were no clinically significant pharmacokinetic differences between the 16-25-year-old group and adults aged over 25 years. 

More than 75% of study participants who were surveyed preferred twice-yearly injectable vs daily oral administration; of these, more than 50% reported a strong preference. 

“Certain groups—including pregnant and lactating women, adolescents and young people—are disproportionately affected by HIV, yet have long been underrepresented in HIV clinical trials,” said Linda-Gail Bekker, Director of the Desmond Tutu HIV Center at the University of Cape Town, South Africa, and former President of the International AIDS Society. “The PURPOSE programme set a new standard for innovative, intentional inclusion by ensuring we would have safety and efficacy data in these populations from the outset.  

“The results not only show that Yeztugo provides strong protection against HIV and was well tolerated in these groups, but also highlight the critical need for PrEP options that reflect people’s preferences—reducing barriers to uptake and helping close persistent gaps in prevention.”

Diana Turner, Senior Digital Content Editor, DDW